摘要
目的 评价胃泌素释放肽前体 ( progastrin releasingpeptide ,ProGRP)作为小细胞肺癌 (SCLC)新标记物的临床意义。方法 回顾性分析经病理证实的 5 5例SCLC初治患者血清中ProGRP水平 ,并观察其与肿瘤分期、治疗效果的关系。结果 ProGRP诊断SCLC的灵敏度为 80 .0 % ,特异度为 97.0 % ;进展期SCLC患者血清ProGRP平均水平显著高于局限期患者 ,二者分别为 82 0 .0ng/L和 2 0 5 .86ng/L (P =0 .0 0 0 3 ) ;临床治疗有效的SCLC患者 ,治疗后ProGRP水平较治疗前明显下降 ,而治疗无效病例则无下降甚至升高。结论 ProGRP作为SCLC新的标记物 ,具有敏感性高、特异性强的特点 ,并可准确反映SCLC病情及对化疗的反应。
Objective To evaluate the significance of progastrin releasing peptide (ProGRP) as a new tumor marker for small cell lung cancer (SCLC). Methods Fifty five patients with pathologically proved SCLC were initially treated and retrospectively studied, in which the level of serum ProGRP was tesed in various situations and its relationship with tumor stage and therapeutic effects was observed. Results The diagnostic sensitivity and specificity of ProGRP to SCLC were 80.0% and 97.0% respectively. The average ProGRP level in extensive disease of SCLC patients was 820.00 ng/L, significantly higher than 205.86 ng/L in limited disease of SCLC patients (P=0.000 3). In chemotherapy sensitive cases, the ProGRP level had a significant decrease after treatment, while there was no change in failure cases. Conclusion ProGRP is a new SCLC tumor marker with high specificity and sensitivity. It has a close relationship with SCLC stage and can be used as a predictor of SCLC to chemotherapy response.
出处
《中国肺癌杂志》
CAS
2003年第3期209-210,共2页
Chinese Journal of Lung Cancer
